June 1, 2017
REDWOOD CITY, Calif. - June 1, 2017 - HeartFlow Inc. has announced the appointment of seasoned healthcare leader Michael Buck as executive vice president and chief commercial officer. Effective immediately, Buck will be responsible for expanding and accelerating global market adoption of the company’s HeartFlow® FFRCT Analysis, the first noninvasive technology to provide insight into both the extent of coronary artery disease and the impact that disease has on blood flow to the heart.
“Mike brings of wealth of valuable commercial leadership experience to HeartFlow at a pivotal growth time for the company,” said John H. Stevens, M.D., chairman and CEO of HeartFlow. “We are thrilled to be adding a professional of his caliber to our executive management team, and look forward to his help in bringing the HeartFlow FFRCT Analysis to every physician and patient who could benefit from it in markets worldwide.”
Buck brings to HeartFlow 25 years of operational experience in global business and product development, licensing and acquisitions, venture investment and commercial sales management. He most recently served as president of the medical products division for Cardinal Health, with global responsibility for the Cardinal brand product portfolio. Prior to Cardinal Health, Buck held several senior leadership roles at Abbott Laboratories, including vice president of global market development, vice president of licensing and acquisitions, and vice president of venture investing. He has also held commercial leadership positions at Novoste Corporation, Boston Scientific and Smith & Nephew.
“HeartFlow’s technology stands to change the way coronary artery disease is diagnosed and managed in health settings across the world,” said Buck. “I am honored to be part of a team with a proven solution that not only improves patient experience and population health, but also drives significant unnecessary cost out of the healthcare system.”
HeartFlow, Inc. is a personalized medical technology company seeking to transform the way cardiovascular disease is diagnosed and treated. The company’s HeartFlow FFRCT Analysis is the first available non-invasive solution that enables a physician to more accurately evaluate whether a patient has significant coronary artery disease (CAD) based on both anatomy and physiology. The solution, which leverages deep learning to create a personalized 3D model of the patient’s arteries, is well positioned to become an integral part of the standard of care for patients who are at risk for CAD because of its potential to improve clinical outcomes, improve the patient experience and reduce the cost of care. The HeartFlow FFRCT Analysis is available in the United States, Canada, Europe and Japan. For more information visit www.heartflow.com.